News archive
Showing 687 results
October 2018
-
Media ReleaseNovartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®-- Kymriah was the first CAR-T cell therapy to ever be approved by a regulatory authority-- Since 1970, more than 40 Novartis innovative therapies have been recognized by the Prix Galien Foundation…
-
Media ReleaseNovartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD- Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept- Superior reductions in central…
-
Media ReleaseTwo-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
-
Media ReleaseNovartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitisNew data show that 73% of ankylosing spondylitis (AS) patients taking Cosentyx® (secukinumab) achieved improvement in AS signs and symptoms at four years, with sustained ASAS response rates1 AS is a…
-
Media ReleaseNovartis presents new Cosentyx® data demonstrating long-term response and safety in ankylosing spondylitis
-
Media ReleaseNovartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study- Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis,…
-
Media ReleaseNovartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
-
Media ReleaseNovartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients- There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS), a highly debilitating form of MS characterized by gradual, irreversible worsening of…
-
Media ReleaseNovartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients
September 2018
-
Media ReleaseNovartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project- Generation S offers the sickle cell community a powerful new way to share personal experiences and rewrite the story of an often-misunderstood disease- Singer-songwriter and actress Jordin Sparks…
-
Media ReleaseNovartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project